SEARCH

SEARCH BY CITATION

References

  • 1
    Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 17311740.
  • 2
    Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811820.
  • 3
    Pucciarelli S, Gagliardi G, Maretto I, Lonardi S, Friso ML, Urso E et al. Long-term oncologic results and complications after preoperative chemoradiotherapy for rectal cancer: a single-institution experience after a median follow-up of 95 months. Ann Surg Oncol 2009; 16: 893899.
  • 4
    Kusters M, Marijnen CA, van de Velde CJ, Rutten HJ, Lahaye MJ, Kim JH et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol 2010; 36: 470476.
  • 5
    Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 665677.
  • 6
    de Campos-Lobato LF, Stocchi L, da Luz Moreira A, Geisler D, Dietz DW, Lavery IC et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol 2011; 18: 15901598.
  • 7
    Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM; Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011; 254: 97102.
  • 8
    Smith KD, Tan D, Das P, Chang GJ, Kattepogu K, Feig BW et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 2010; 251: 261264.
  • 9
    Bedrosian I, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA et al. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg 2004; 8: 5662.
  • 10
    Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240: 711717.
  • 11
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
  • 12
    Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603605.
  • 13
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557560.
  • 14
    Avallone A, Delrio P, Pecori B, Tatangelo F, Petrillo A, Scott N et al. Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome. Int J Radiat Oncol Biol Phys 2011; 79: 670676.
  • 15
    Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99107.
  • 16
    Ciccocioppo A, Stephens JH, Hewett PJ, Rieger NA. Complete pathologic response after preoperative rectal cancer chemoradiotherapy. ANZ J Surg 2009; 79: 481484.
  • 17
    Hong YS, Kim DY, Lim SB, Choi HS, Jeong SY, Jeong JY et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study. Int J Radiat Oncol Biol Phys 2011; 79: 11711178.
  • 18
    Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys 2011; 81: 677683.
  • 19
    Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004; 47: 17981807.
  • 20
    Rödel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 86888696.
  • 21
    Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 51245130.
  • 22
    Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236: 7581.
  • 23
    Shivnani AT, Small W Jr, Stryker SJ, Kiel KD, Lim S, Halverson AL et al. Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg 2007; 193: 389393.
  • 24
    Valentini V, De Paoli A, Gambacorta MA, Mantini G, Ratto C, Vecchio FM et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiat Oncol Biol Phys 2008; 72: 644649.
  • 25
    Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum 2004; 47: 20252031.
  • 26
    Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 2010; 252: 9981004.
  • 27
    SEER Program (National Cancer Institute (US)), National Institutes of Health (US), National Cancer Institute (US). Surveillance Program. SEER cancer statistics review. In NIH Publication. US Dept of Health and Human Services, Public Health Institute: Bethesda, 2009; v.
  • 28
    Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 14791482.
  • 29
    Wibe A, Møller B, Norstein J, Carlsen E, Wiig JN, Heald RJ et al.; Norwegian Rectal Cancer Group. A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857866.
  • 30
    Carlsen E, Schlichting E, Guldvog I, Johnson E, Heald RJ. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg 1998; 85: 526529.
  • 31
    Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P et al.; European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 43794386.
  • 32
    Moore E, Heald RJ, Cecil TD, Sharpe GD, Sexton R, Moran BJ. Almost all five year disease free survivors are cured following rectal cancer surgery, but longer term follow-up detects some late local and systemic recurrences. Colorectal Dis 2005; 7: 403405.
  • 33
    Barras JP, Bachmann R, Aeberhard P. Pattern of recurrence in rectal carcinoma: implications for the design of (future) studies on adjuvant therapy. Int J Colorectal Dis 1993; 8: 142147.
  • 34
    Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53: 13541362.
  • 35
    Hurst PA, Prout WG, Kelly JM, Bannister JJ, Walker RT. Local recurrence after low anterior resection using the staple gun. Br J Surg 1982; 69: 275276.
  • 36
    Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T et al.; Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693701.
  • 37
    Ahmad NR, Nagle D. Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer. Br J Surg 1997; 84: 14451448.
  • 38
    Lopez-Kostner F, Fazio VW, Vignali A, Rybicki LA, Lavery IC. Locally recurrent rectal cancer: predictors and success of salvage surgery. Dis Colon Rectum 2001; 44: 173178.
  • 39
    Garcia-Aguilar J, Cromwell JW, Marra C, Lee SH, Madoff RD, Rothenberger DA. Treatment of locally recurrent rectal cancer. Dis Colon Rectum 2001; 44: 17431748.
  • 40
    Hahnloser D, Nelson H, Gunderson LL, Hassan I, Haddock MG, O'Connell MJ et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg 2003; 237: 502508.
  • 41
    Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835844.
  • 42
    Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 2001; 8: 801806.
  • 43
    Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C et al.; Radiation Therapy Oncology GroupTrial 0012. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650655.
  • 44
    Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241248.
  • 45
    Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009; 27: 27512757.
  • 46
    Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval > 7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008; 15: 26612667.
  • 47
    Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009; 250: 582589.
  • 48
    Coco C, Manno A, Mattana C, Verbo A, Rizzo G, Valentini V et al. The role of local excision in rectal cancer after complete response to neoadjuvant treatment. Surg Oncol 2007; 16(Suppl 1): S101S104.
  • 49
    Nair RM, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Malafa MP et al. Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J Gastrointest Surg 2008; 12: 17971805.
  • 50
    Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M et al. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys 2004; 60: 10981105.
  • 51
    Kim CJ, Yeatman TJ, Coppola D, Trotti A, Williams B, Barthel JS et al. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg 2001; 234: 352358.
  • 52
    Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol 2010; 17: 441447.
  • 53
    Schell SR, Zlotecki RA, Mendenhall WM, Marsh RW, Vauthey JN, Copeland EM III. Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy. J Am Coll Surg 2002; 194: 584590.
  • 54
    Lezoche E, Guerrieri M, Paganini AM, Baldarelli M, De Sanctis A, Lezoche G. Long-term results in patients with T2–3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery. Br J Surg 2005; 92: 15461552.
  • 55
    Mignanelli ED, de Campos-Lobato LF, Stocchi L, Lavery IC, Dietz DW. Downstaging after chemoradiotherapy for locally advanced rectal cancer: is there more (tumor) than meets the eye? Dis Colon Rectum 2010; 53: 251256.
  • 56
    Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum 2004; 47: 825831.
  • 57
    Seong J, Cho JH, Kim NK, Min JS, Suh CO. Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer. Int J Radiat Oncol Biol Phys 2001; 50: 435439.
  • 58
    Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002; 194: 131135.
  • 59
    Hughes R, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M et al. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3–T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis 2006; 21: 1117.
  • 60
    Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006; 10: 13191328.